Skip to content

A large sample, multi-center randomized controlled trial of moxibustion combined with Yiqen-yang-Huoxue prescription in the treatment of chronic stable labor angina pectoris

A large sample, multi-center randomized controlled trial of moxibustion combined with Yiqen-yang-Huoxue prescription in the treatment of chronic stable labor angina pectoris

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069782
Enrollment
Unknown
Registered
2023-03-24
Start date
2023-03-27
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Moxibustion medicine combined with intervention group:moxibustion combined with Yiqen-yang-Huoxuei formula

Sponsors

Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 74 Years

Inclusion criteria

Inclusion criteria: (1) Age between 35 and 74 years old (including boundary values), gender unlimited; (2) consistent with the western diagnostic criteria for stable angina pectoris of coronary heart disease; (3) The history of stable angina pectoris should not be less than 2 months; (4) The average number of angina attacks per week in the month before inclusion was =1; (5) Canadian Cardiovascular Society (CCS) angina grade ? -- ?; (6) Sign informed consent.

Exclusion criteria

Exclusion criteria: (1) myocardial infarction in the last 3 months; (2) Patients who have received PCI or other heart surgery (such as CABG) within the last 1 year; (3) Patients who plan to undergo coronary revascularization (CABG or PCI) within 2 months; (4) Patients with unstable angina pectoris, refractory heart failure, cardiogenic shock, severe valvular heart disease and other serious cardiovascular diseases; (5) Patients with poor hypertension control (systolic blood pressure =160mmHg or diastolic blood pressure =100mmHg after treatment); (6) Patients with severe respiratory diseases such as severe pulmonary insufficiency; (7) Liver insufficiency (alanine aminotransferase or aspartate aminotransferase level is more than 2 times higher than the normal value), renal insufficiency (creatinine level is more than 2 times higher than the normal value) and other serious liver and kidney diseases; (8) Patients with malignant tumor, severe anemia, severe renal artery stenosis and other serious diseases or conditions; (9) Patients with contraindications to exercise treadmill test (see Annex 1 for details); (10) Participated in other clinical researchers within the last 2 months; (11) Allergic to known components of the investigational drug; (12) Pregnancy test positive, pregnancy planning or breastfeeding women; (13) Researchers with recent infections, injuries, etc., were judged not to participate in the study. (14) Intolerant to moxa tobacco.

Design outcomes

Primary

MeasureTime frame
Exercise plate test;Seattle Angina Questionnaire;Frequency of angina attacks;

Countries

China

Contacts

Public ContactWu Jianguang

Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine

wjgnc@sina.com13907003803

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026